BiotechTube

Epcoritamab + Epcoritamab + rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone + Venetoclax + Epcoritamab + Lenalidomide + Epcoritamab + Pirtobrutinib + Epcoritamab

Phase 1/2Active
0 watching 0 views this week⚡ Active
41
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Relapsed/Refractory Chronic Lymphocytic Leukemia

Conditions

Relapsed/Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Richter's Syndrome, Treatment-naïve High Risk Chronic Lymphocytic Leukemia

Trial Timeline

Nov 25, 2020 → Feb 1, 2028

NCT ID
NCT04623541

About Epcoritamab + Epcoritamab + rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone + Venetoclax + Epcoritamab + Lenalidomide + Epcoritamab + Pirtobrutinib + Epcoritamab

Epcoritamab + Epcoritamab + rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone + Venetoclax + Epcoritamab + Lenalidomide + Epcoritamab + Pirtobrutinib + Epcoritamab is a phase 1/2 stage product being developed by Eli Lilly for Relapsed/Refractory Chronic Lymphocytic Leukemia. The current trial status is active. This product is registered under clinical trial identifier NCT04623541. Target conditions include Relapsed/Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Richter's Syndrome.

Hype Score Breakdown

Clinical
13
Activity
8
Company
10
Novelty
4
Community
3

Clinical Trials (1)

NCT IDPhaseStatus
NCT04623541Phase 1/2Active

Competing Products

20 competing products in Relapsed/Refractory Chronic Lymphocytic Leukemia

See all competitors
ProductCompanyStageHype Score
agenT-797MiNK TherapeuticsPhase 1
25
Valemetostat TosylateDaiichi SankyoPhase 2
52
Eribulin mesylateEisaiPhase 2
52
Tirabrutinib + Rituximab + TemozolomideOno PharmaceuticalPhase 3
77
ISB 1342Glenmark PharmaceuticalsPhase 1
33
SHR2554; Chidamide analog tablets + SHR2554 analog tablets; ChidamideJiangsu Hengrui MedicinePhase 3
77
Linperlisib ； RituximabJiangsu Hengrui MedicinePhase 1/2
41
Epcoritamab + Epcoritamab, lenalidomide and rituximabAbbViePhase 2
52
EtentamigAbbViePhase 1
33
Venetoclax + Bortezomib + Dexamethasone + Placebo for venetoclaxAbbViePhase 3
77
Etentamig + Dexamethasone + Lenalidomide + Pomalidomide + DaratumumabAbbViePhase 1
33
[14C]ABT-199 (GDC-0199)AbbViePhase 1
33
ABT-199 + bortezomib + dexamethasoneAbbViePhase 1
33
Venetoclax + DexamethasoneAbbViePhase 1/2
41
ABBV-453 + Dexamethasone + Daratumumab + LenalidomideAbbViePhase 1
33
mRNA-2752 + DurvalumabAstraZenecaPhase 1
33
AZD4573AstraZenecaPhase 2
52
Moxetumomab PasudotoxAstraZenecaPre-clinical
23
Administration of AZD6738AstraZenecaPhase 1
33
BlinatumomabAmgenPhase 2
51

Other Products from Eli Lilly

Insulin Glargine + Insulin Lispro Premix (mid-mixture and low-mixture)Approved
85
Olanzapine + PlaceboApproved
85
exenatide and sitagliptin + exenatide and placeboApproved
85
Tirzepatide + PlaceboApproved
85
tadalafilApproved
85